Filing Details

Accession Number:
0001655759-24-000028
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-27 18:35:17
Reporting Period:
2024-02-23
Accepted Time:
2024-02-27 18:35:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1655759 Arvinas Inc. ARVN Pharmaceutical Preparations (2834) 472566120
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753537 G John Houston C/O Arvinas, Inc.
5 Science Park, 395 Winchester Ave.
New Haven CT 06511
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-23 124,450 $0.00 1,041,877 No 4 A Direct
Common Stock Disposition 2024-02-23 5,196 $47.05 1,036,681 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-02-23 184,200 $0.00 184,200 $47.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
184,200 2034-02-22 No 4 A Direct
Footnotes
  1. The restricted stock units (each, an "RSU") were granted by the Issuer on February 23, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.
  2. This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.
  3. The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.